1
|
Cevik O, Baykal AT, Sener A. Platelets Proteomic Profiles of Acute Ischemic Stroke Patients. PLoS One 2016; 11:e0158287. [PMID: 27336623 PMCID: PMC4919045 DOI: 10.1371/journal.pone.0158287] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Accepted: 06/13/2016] [Indexed: 12/20/2022] Open
Abstract
Platelets play a crucial role in the pathogenesis of stroke and antiplatelet agents exist for its treatment and prevention. Through the use of LC-MS based protein expression profiling, platelets from stroke patients were analyzed and then correlated with the proteomic analyses results in the context of this disease. This study was based on patients who post ischemic stroke were admitted to hospital and had venous blood drawn within 24 hrs of the incidence. Label-free protein expression analyses of the platelets' tryptic digest was performed in triplicate on a UPLC-ESI-qTOF-MS/MS system and ProteinLynx Global Server (v2.5, Waters) was used for tandem mass data extraction. The peptide sequences were searched against the reviewed homo sapiens database (www.uniprot.org) and the quantitation of protein variation was achieved through Progenesis LC-MS software (V4.0, Nonlinear Dynamics). These Label-free differential proteomics analysis of platelets ensured that 500 proteins were identified and 83 of these proteins were found to be statistically significant. The differentially expressed proteins are involved in various processes such as inflammatory response, cellular movement, immune cell trafficking, cell-to-cell signaling and interaction, hematological system development and function and nucleic acid metabolism. The expressions of myeloperoxidase, arachidonate 12-Lipoxygenase and histidine-rich glycoprotein are involved in cellular metabolic processes, crk-like protein and ras homolog gene family member A involved in cell signaling with vitronectin, thrombospondin 1, Integrin alpha 2b, and integrin beta 3 involved in cell adhesion. Apolipoprotein H, immunoglobulin heavy constant gamma 1 and immunoglobulin heavy constant gamma 3 are involved in structural, apolipoprotein A-I, and alpha-1-microglobulin/bikunin precursor is involved in transport, complement component 3 and clusterin is involved in immunity proteins as has been discussed. Our data provides an insight into the proteins that are involved in the platelets' activation response during ischemic stroke. It could be argued that this study lays the foundation for future mechanistic studies.
Collapse
Affiliation(s)
- Ozge Cevik
- Cumhuriyet University, Faculty of Pharmacy, Department of Biochemistry, Sivas, Turkey
- Marmara University, Faculty of Pharmacy, Department of Biochemistry, Istanbul, Turkey
- * E-mail:
| | - Ahmet Tarik Baykal
- Acibadem University, School of Medicine, Department of Medical Biochemistry, Istanbul, Turkey
| | - Azize Sener
- Marmara University, Faculty of Pharmacy, Department of Biochemistry, Istanbul, Turkey
| |
Collapse
|
4
|
Parguiña AF, Grigorian-Shamagian L, Agra RM, López-Otero D, Rosa I, Alonso J, Teijeira-Fernández E, González-Juanatey JR, García Á. Variations in Platelet Proteins Associated With ST-Elevation Myocardial Infarction. Arterioscler Thromb Vasc Biol 2011; 31:2957-64. [DOI: 10.1161/atvbaha.111.235713] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Our aim in this study was to provide novel information on the molecular mechanisms playing a major role in the unwanted platelet activation associated with ST-elevation myocardial infarction (STEMI).
Methods and Results—
We compared the platelet proteome of 11 STEMI patients to a matched control group of 15 stable chronic ischemic cardiopathy patients. In addition, we did a prospective study to follow the STEMI patients over time. Proteins were separated by high-resolution 2D gel electrophoresis, identified by mass spectrometry, and validated by Western blotting. Platelets from STEMI patients on admission displayed 56 protein spot differences (corresponding to 42 unique genes) compared with the control group. The number of differences decreased with time during the patients' follow-up. Interestingly, the adapter protein CrkL and the active form of Src (phosphorylated in Tyr418) were found to be upregulated in platelets from STEMI patients. Major signaling pathways related to the proteins identified include integrin, integrin-linked kinase, and glycoprotein VI (GPVI) signaling. Interestingly, a study on an independent cohort of patients showed a higher degree of activation of GPVI signaling in STEMI patients.
Conclusion—
CrkL, the active form of Src, and GPVI signaling are upregulated in platelets from STEMI patients.
Collapse
Affiliation(s)
- Andrés F. Parguiña
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Lilian Grigorian-Shamagian
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Rosa M. Agra
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Diego López-Otero
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Isaac Rosa
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Jana Alonso
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Elvis Teijeira-Fernández
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - José Ramón González-Juanatey
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| | - Ángel García
- From the Department of Pharmacology, Faculty of Pharmacy (A.F.P., I.R., A.G.) and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) (A.F.P., I.R., A.G.), Universidade de Santiago de Compostela, Santiago de Compostela, Spain; Cardiology Department, Complexo Hospitalario Universitario de Vigo, Vigo, Spain (L.G.-S.); Cardiology Department and Coronary Unit (L.G.-S., R.M.A., D.L.-O., E.T.-F., J.R.G.-J.) and Proteomic Unit, Instituto de Investigaciones Sanitarias (J.A.), Hospital
| |
Collapse
|
8
|
García A, Senis YA, Antrobus R, Hughes CE, Dwek RA, Watson SP, Zitzmann N. A global proteomics approach identifies novel phosphorylated signaling proteins in GPVI-activated platelets: involvement of G6f, a novel platelet Grb2-binding membrane adapter. Proteomics 2006; 6:5332-43. [PMID: 16941570 PMCID: PMC1869047 DOI: 10.1002/pmic.200600299] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Collagen-related peptide (CRP) stimulates powerful activation of platelets through the glycoprotein VI (GPVI)-FcR gamma-chain complex. We have combined proteomics and traditional biochemistry approaches to study the proteome of CRP-activated platelets, focusing in detail on tyrosine phosphorylation. In two separate approaches, phosphotyrosine immunoprecipitations followed by 1-D-PAGE, and 2-DE, were used for protein separation. Proteins were identified by MS. By following these approaches, 96 proteins were found to undergo PTM in response to CRP in human platelets, including 11 novel platelet proteins such as Dok-1, SPIN90, osteoclast stimulating factor 1, and beta-Pix. Interestingly, the type I transmembrane protein G6f was found to be specifically phosphorylated on Tyr-281 in response to platelet activation by CRP, providing a docking site for the adapter Grb2. G6f tyrosine phoshporylation was also found to take place in response to collagen, although not in response to the G protein-coupled receptor agonists, thrombin and ADP. Further, we also demonstrate for the first time that Grb2 and its homolog Gads are tyrosine-phosphorylated in CRP-stimulated platelets. This study provides new insights into the mechanism of platelet activation through the GPVI collagen receptor, helping to build the basis for the development of new drug targets for thrombotic disease.
Collapse
Affiliation(s)
- Angel García
- Department of Biochemistry, Oxford Glycobiology Institute, University of Oxford, Oxford, UK.
| | | | | | | | | | | | | |
Collapse
|
9
|
Kubota Y, Tanaka T, Ohnishi H, Kitanaka A, Okutani Y, Taminato T, Ishida T, Kamano H. Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. Leukemia 2004; 18:1127-37. [PMID: 15085152 DOI: 10.1038/sj.leu.2403370] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In this study, we examined the effect of thrombopoietin (TPO) on the aggregation of platelets from 40 patients with myeloproliferative disorders (MPDs), including 17 patients with chronic myelogenous leukemia in the chronic phase (CML-CP), 10 with polycythemia vera, 10 with essential thrombocythemia, and three with myelofibrosis. TPO by itself dose-dependently induced the aggregation of platelets from patients with CML-CP but not from those with other MPDs or with CML-CP in cytogenetical complete remission. The expression of CD63 in CML-CP platelets was induced by TPO treatment. Phosphatidylinositol 3-kinase (PI3-kinase) was constitutively activated in CML-CP platelets. Pretreatment with PI3-kinase inhibitors (wortmannin and LY294002) dose-dependently inhibited TPO-induced aggregation of CML-CP platelets. The Abl kinase inhibitor imatinib mesylate and the Jak inhibitor AG490 suppressed TPO-induced aggregation of CML-CP platelets. Pretreatment with imatinib mesylate, but not with AG490, inhibited the activity of PI3-kinase in CML-CP platelets. In addition, tyrosine phosphorylation of Jak2 was undetected in CML-CP platelets before TPO treatment. These findings indicate that the constitutive activation of PI3-kinase primes CML-CP platelets for the aggregation induced by TPO, and that Bcr-Abl, but not Jak family protein tyrosine kinases, are involved in the constitutive activation of PI3-kinase in CML-CP platelets.
Collapse
Affiliation(s)
- Y Kubota
- The Department of Transfusion Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
| | | | | | | | | | | | | | | |
Collapse
|